» Articles » PMID: 33927716

Metabolites in the Tumor Microenvironment Reprogram Functions of Immune Effector Cells Through Epigenetic Modifications

Overview
Journal Front Immunol
Date 2021 Apr 30
PMID 33927716
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Cellular metabolism of both cancer and immune cells in the acidic, hypoxic, and nutrient-depleted tumor microenvironment (TME) has attracted increasing attention in recent years. Accumulating evidence has shown that cancer cells in TME could outcompete immune cells for nutrients and at the same time, producing inhibitory products that suppress immune effector cell functions. Recent progress revealed that metabolites in the TME could dysregulate gene expression patterns in the differentiation, proliferation, and activation of immune effector cells by interfering with the epigenetic programs and signal transduction networks. Nevertheless, encouraging studies indicated that metabolic plasticity and heterogeneity between cancer and immune effector cells could provide us the opportunity to discover and target the metabolic vulnerabilities of cancer cells while potentiating the anti-tumor functions of immune effector cells. In this review, we will discuss the metabolic impacts on the immune effector cells in TME and explore the therapeutic opportunities for metabolically enhanced immunotherapy.

Citing Articles

Tumor cells escape immunosurveillance by hampering LFA-1.

Upadhyay S, Murugu L, Svensson L Front Immunol. 2025; 16:1519841.

PMID: 39911389 PMC: 11794523. DOI: 10.3389/fimmu.2025.1519841.


Antibody-Based Immunotherapies for the Treatment of Hematologic Malignancies.

Jureczek J, Kalwak K, Dziegiel P Cancers (Basel). 2025; 16(24.

PMID: 39766080 PMC: 11674729. DOI: 10.3390/cancers16244181.


Changes in tumor and cardiac metabolism upon immune checkpoint.

Leven A, Wagner N, Nienaber S, Messiha D, Tasdogan A, Ugurel S Basic Res Cardiol. 2024; 120(1):133-152.

PMID: 39658699 PMC: 11790718. DOI: 10.1007/s00395-024-01092-8.


Harnessing CD8 T cell dynamics in hepatitis B virus-associated liver diseases: Insights, therapies and future directions.

Yue B, Gao Y, Hu Y, Zhan M, Wu Y, Lu L Clin Transl Med. 2024; 14(7):e1731.

PMID: 38935536 PMC: 11210506. DOI: 10.1002/ctm2.1731.


Editorial: Tumor microenvironment and hematological malignancies: new evidences and new questions.

Fiorcari S, Strati P, Dondi E Front Immunol. 2024; 15:1407981.

PMID: 38690284 PMC: 11059779. DOI: 10.3389/fimmu.2024.1407981.


References
1.
Ali A, Makings J, Ley K . Regulatory T Cell Stability and Plasticity in Atherosclerosis. Cells. 2020; 9(12). PMC: 7764358. DOI: 10.3390/cells9122665. View

2.
Henderson T, Ness K, Cohen H . Accelerated aging among cancer survivors: from pediatrics to geriatrics. Am Soc Clin Oncol Educ Book. 2014; :e423-30. DOI: 10.14694/EdBook_AM.2014.34.e423. View

3.
Hyun K, Jeon J, Park K, Kim J . Writing, erasing and reading histone lysine methylations. Exp Mol Med. 2017; 49(4):e324. PMC: 6130214. DOI: 10.1038/emm.2017.11. View

4.
Warburg O, Wind F, Negelein E . THE METABOLISM OF TUMORS IN THE BODY. J Gen Physiol. 2009; 8(6):519-30. PMC: 2140820. DOI: 10.1085/jgp.8.6.519. View

5.
Verdone L, Agricola E, Caserta M, Di Mauro E . Histone acetylation in gene regulation. Brief Funct Genomic Proteomic. 2006; 5(3):209-21. DOI: 10.1093/bfgp/ell028. View